FDA, Agendia To Determine Scope Of MammaPrint Premarket Regulation
This article was originally published in The Gray Sheet
Executive Summary
Agendia's MammaPrint breast cancer recurrence assay may qualify for a CLIA waiver and require no further premarket regulation, the company says
You may also be interested in...
Exagen Files First Of Six Planned 510(k)s For Genomic Test Kits
Exagen Diagnostics recently filed the first of six planned 510(k) applications for test kits developed using its novel Coperna computational platform, kicking off a major push into the nascent genomic test kit market
Exagen Files First Of Six Planned 510(k)s For Genomic Test Kits
Exagen Diagnostics recently filed the first of six planned 510(k) applications for test kits developed using its novel Coperna computational platform, kicking off a major push into the nascent genomic test kit market
Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule
FDA should start over in its efforts to claim regulatory oversight of a new class of high-tech laboratory-developed tests through a guidance document and begin a formal rulemaking process, diagnostic industry stakeholders said at a Feb. 8 hearing